- Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- - Selecta to receive a $2 million payment from Sarepta extending their option periods under the agreement to Q1 2023- -Enrollment in DISSOLVE II, the
WATERTOWN, Mass. , May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to
– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 – – DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 – – Completed underwritten offering, raising approximately $38.7 million in gross proceeds, extending runway into
Data to be featured in two oral presentations and four poster presentations WATERTOWN, Mass. , May 02, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR ® platform to develop tolerogenic therapies for autoimmune
WATERTOWN, Mass. , April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR ® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a
WATERTOWN, Mass. , April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, today announced that it has agreed to sell 27,428,572 shares of its
WATERTOWN, Mass. , April 04, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR ® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s
– U.S. Food and Drug Administration (“FDA”) removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia (“MMA”)- -Observed the synergy of ImmTOR in combination with engineered Treg-selective IL-2 to expand antigen-specific Tregs and improve durability of immune
WATERTOWN, Mass. , Feb. 09, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management
